Initial expectations for genome-wide association studies were high, as such studies
promised to rapidly transform personalized medicine with individualized disease risk …

Judgement, as one of the core tenets of medicine, relies upon the integration of multilayered
data with nuanced decision making. Cancer offers a unique context for medical decisions …

Background Between 1999 and 2009 in the United Kingdom, 82,429 men between 50 and
69 years of age received a prostate-specific antigen (PSA) test. Localized prostate cancer …

Background Screening for prostate cancer is burdened by a high rate of overdiagnosis. The
most appropriate algorithm for population-based screening is unknown. Methods We invited …

Purpose: The summary presented herein represents Part I of the three-part series dedicated
to Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, discussing risk assessment …

Background Localised prostate cancer is commonly treated with external-beam
radiotherapy. Moderate hypofractionation has been shown to be non-inferior to conventional …

Background Adjuvant radiotherapy reduces the risk of biochemical progression in prostate
cancer patients after radical prostatectomy. We aimed to compare adjuvant versus early …

Background Multiparametric magnetic resonance imaging (MRI), with or without targeted
biopsy, is an alternative to standard transrectal ultrasonography–guided biopsy for prostate …

Background The use of 12-core systematic prostate biopsy is associated with diagnostic
inaccuracy that contributes to both overdiagnosis and underdiagnosis of prostate cancer …

Importance In the United States, the lifetime risk of being diagnosed with prostate cancer is
approximately 11%, and the lifetime risk of dying of prostate cancer is 2.5%. The median age …